Association of pneumococcal serotype with susceptibility to antimicrobial drugs: a systematic review and meta-analysis

Author(s):  
Kristin Andrejko ◽  
Buddhika Ratnasiri ◽  
Joseph A Lewnard

Abstract Background Pneumococcal serotypes differ in antimicrobial susceptibility. However, patterns and causes of this variation are not comprehensively understood. Methods We undertook a systematic review of epidemiologic studies of pneumococci isolated from carriage or invasive disease among children globally from 2000-2019. We evaluated associations of each serotype with nonsusceptibility to penicillin, macrolides, and trimethoprim/sulfamethoxazole. We evaluated differences in the prevalence of nonsusceptibility to major antibiotic classes across serotypes using random effects meta-regression models, and assessed changes in prevalence of nonsusceptibility after implementation of pneumococcal conjugate vaccines (PCVs). We also evaluated associations between biological characteristics of serotypes and their likelihood of nonsusceptibility to each drug. Results We included data from 129 studies representing 32,187 isolates across 52 countries. Within serotypes, the proportion of nonsusceptible isolates varied geographically and over time, in settings using and those not using PCVs. Factors predicting enhanced fitness of serotypes in colonization as well as enhanced pathogenicity were each associated with higher likelihood of nonsusceptibility to penicillin, macrolides, and trimethoprim/sulfamethoxazole. Increases in prevalence of nonsusceptibility following PCV implementation were evident among non-PCV serotypes including 6A, 6C, 15A, 15B/C, 19A, and 35B; however, this pattern was not universally evident among non-PCV serotypes. Post-vaccination increases in nonsusceptibility for serotypes 6A and 19A were attenuated in settings that implemented PCV13. Conclusions In pneumococci, nonsusceptibility to penicillin, macrolides, and trimethoprim/sulfamethoxazole is associated with more frequent opportunities for antibiotic exposure during both prolonged carriage episodes and when serotypes cause disease. These findings suggest multiple pathways leading to resistance selection in pneumococci.

2017 ◽  
Vol 16 (1) ◽  
Author(s):  
Jeavana Sritharan ◽  
Manisha Pahwa ◽  
Paul A. Demers ◽  
Shelley A. Harris ◽  
Donald C. Cole ◽  
...  

Vaccine ◽  
2017 ◽  
Vol 35 (43) ◽  
pp. 5776-5785 ◽  
Author(s):  
Cristiano Alicino ◽  
Chiara Paganino ◽  
Andrea Orsi ◽  
Matteo Astengo ◽  
Cecilia Trucchi ◽  
...  

2018 ◽  
Vol 77 (5) ◽  
pp. 368-378 ◽  
Author(s):  
Evelyn Balsells ◽  
Ron Dagan ◽  
Inci Yildirim ◽  
Prabhu P. Gounder ◽  
Anneke Steens ◽  
...  

2008 ◽  
Vol 16 (2) ◽  
pp. 222-229 ◽  
Author(s):  
H. Findlow ◽  
G. Laher ◽  
P. Balmer ◽  
C. Broughton ◽  
E. D. Carrol ◽  
...  

ABSTRACT Traditional confirmation procedures for the identification of a pneumococcal serotype require an isolate. Non-culture-based confirmation protocols are available. Some of these confirm only the presence of pneumococci, and others are capable of identifying a limited number of serotypes. The increased use of pneumococcal polysaccharide and conjugate vaccines, especially in high-risk patient groups, and the likely increase in the number of serotypes included in future versions of the conjugate vaccines have necessitated the need for improved enhanced surveillance in order to assess their impact on public health. Since 2006, a multiplexed assay has been used at the Health Protection Agency of the United Kingdom for the detection of 14 pneumococcal serotypes which requires pneumococcal serotype-specific monoclonal antibodies (MAbs). We have developed a microsphere competitive inhibition method capable of detecting 23 pneumococcal capsular polysaccharide serotypes in cerebrospinal fluid (CSF) and urine and serotyping pneumococcal suspensions, utilizing an international reference serum, 89-SF. The assay was shown to be reproducible and specific for homologous polysaccharide. Validation of the assay was performed with a selection of MAbs specific for pneumococcal capsular polysaccharide serotypes, which confirmed the specificity of the assay. Analysis of pneumolysin PCR-positive CSF samples in the competitive inhibition assay determined a serotype for 89% of the samples. The assay developed here is well suited to large-scale epidemiologic studies because the assay is simple, robust, and rapid and utilizes readily available resources.


Sign in / Sign up

Export Citation Format

Share Document